Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Morgan Stanley Downgrades Maravai LifeSciences to Equal-Weight, Lowers Price Target to $10

Author: Benzinga Newsdesk | August 13, 2024 05:22am
Morgan Stanley analyst Tejas Savant downgrades Maravai LifeSciences (NASDAQ:MRVI) from Overweight to Equal-Weight and lowers the price target from $11 to $10.

Posted In: MRVI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist